MCID: RHM027
MIFTS: 62

Rheumatic Disease

Categories: Cardiovascular diseases, Immune diseases

Aliases & Classifications for Rheumatic Disease

MalaCards integrated aliases for Rheumatic Disease:

Name: Rheumatic Disease 12 15
Rheumatic Diseases 55
Collagen Diseases 73
Rheumatism 73

Classifications:



External Ids:

Disease Ontology 12 DOID:1575
ICD10 33 I06.9 I09.9
UMLS 73 C0035435

Summaries for Rheumatic Disease

Disease Ontology : 12 A hypersensitivity reaction type II disease that involves inflammation or pain in the muscles, joints, or fibrous tissue.

MalaCards based summary : Rheumatic Disease, also known as rheumatic diseases, is related to spondyloarthropathy 1 and palindromic rheumatism, and has symptoms including musculoskeletal symptom, myalgia and joint symptom. An important gene associated with Rheumatic Disease is TNF (Tumor Necrosis Factor), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Methotrexate and Hydroxychloroquine have been mentioned in the context of this disorder. Affiliated tissues include bone, testes and heart, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Related Diseases for Rheumatic Disease

Diseases related to Rheumatic Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 388)
# Related Disease Score Top Affiliating Genes
1 spondyloarthropathy 1 32.7 CD40LG CRP HLA-B TNF
2 palindromic rheumatism 32.4 CRP HLA-DRB1 IL1B TNF
3 arthritis 30.7 HLA-DRB1 IFNG IL10 IL1B PTGS2 TNF
4 arteries, anomalies of 30.6 CRP IL1B TNF VCAM1
5 psoriatic arthritis 30.6 CRP HLA-B HLA-DRB1 IL1B TNF
6 joint disorders 30.5 IL1B IL1R1 TNF
7 spondylitis 30.5 CD40LG CRP HLA-B TNF
8 cystitis 30.5 CRP PTGS2 TNF
9 chikungunya 30.3 CD40LG IL1B TNF
10 synovitis 30.3 CRP IL1B TNF VCAM1
11 peptic ulcer disease 30.2 IL10 IL1B PTGS2 TNF
12 bronchiolitis obliterans 30.2 IFNG IL10 TNF
13 hematopoietic stem cell transplantation 30.2 HLA-B IFNG IL10 TNF
14 chronic fatigue syndrome 30.2 IL10 IL1B TNF
15 interstitial lung disease 30.1 IFNG IL10 IL1B TNF
16 reactive arthritis 29.9 CRP HLA-B IFNG IL10 TNF
17 mumps 29.9 CD40LG HLA-DRB1 IFNG TNF
18 pneumonia 29.9 CD40LG CRP IL10 IL1B TNF
19 leishmaniasis 29.8 HLA-DRB1 IFNG IL10 IL1B TNF
20 bronchiolitis 29.6 CD40LG IFNG IL10 TNF
21 vasculitis 29.6 APOH CD40LG CRP TNF VCAM1
22 sjogren syndrome 29.6 APOH SSB TRIM21
23 demyelinating disease 29.6 CD40LG IFNG IL10 IL1B TNF
24 syphilis 29.5 APOH CD40LG HLA-DRB1
25 rubella 29.5 CD40LG HLA-B HLA-DRB1 IL10 TNF
26 tetanus 29.4 CD40LG IFNG IL10 IL2RA
27 uveitis 29.3 HLA-B IFNG IL10 IL1R1 IL2RA TNF
28 lupus erythematosus 29.2 APOH CD40LG IL10 SSB TNF TRIM21
29 myocardial infarction 29.2 CD40LG CRP IL10 IL1B PTGS2 TNF
30 rheumatoid arthritis 29.1 CD40LG CRP HLA-B HLA-DRB1 HMGB1 IFNG
31 chlamydia 29.1 CD40LG CRP IFNG IL10 IL1B TNF
32 mixed connective tissue disease 29.0 CD40LG HLA-DRB1 IFNG IL10 RNPC3 TNF
33 temporal arteritis 29.0 APOH CD40LG CRP HLA-DRB1 IFNG
34 inflammatory bowel disease 28.1 CRP HLA-B HLA-DRB1 IFNG IL10 IL1B
35 connective tissue disease 27.0 APOH CD40LG CENPB HLA-DRB1 IFNG IL10
36 systemic lupus erythematosus 27.0 APOH CD40LG CRP HLA-DRB1 HMGB1 IFNG
37 enthesopathy 11.5
38 macrophage activation syndrome 11.2
39 postherpetic neuralgia 11.1 HLA-B HLA-DRB1
40 rheumatic pulmonary valve disease 11.0
41 nontuberculous mycobacterial lung disease 11.0 HLA-B HLA-DRB1 TNF
42 alveolar echinococcosis 11.0 HLA-B HLA-DRB1 TNF
43 anca-associated vasculitis 11.0 HLA-DRB1 HMGB1 TNF
44 punctate inner choroidopathy 11.0 IL10 TNF
45 idiopathic inflammatory myopathy 11.0 HLA-B HLA-DRB1 TRIM21
46 geographic tongue 10.9 HLA-B HLA-DRB1 TNF
47 cytomegalovirus retinitis 10.9 HLA-B IFNG TNF
48 chronic beryllium disease 10.9 HLA-DRB1 IFNG TNF
49 autoimmune myocarditis 10.9 IFNG IL1B TNF
50 systemic onset juvenile idiopathic arthritis 10.9 IL1B TNF

Graphical network of the top 20 diseases related to Rheumatic Disease:



Diseases related to Rheumatic Disease

Symptoms & Phenotypes for Rheumatic Disease

UMLS symptoms related to Rheumatic Disease:


musculoskeletal symptom, myalgia, joint symptom

GenomeRNAi Phenotypes related to Rheumatic Disease according to GeneCards Suite gene sharing:

26 (show all 17)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-104 10.03 IL2RA
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-109 10.03 HMGB1
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-134 10.03 IL2RA
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-141 10.03 APOH
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-153 10.03 SSB HMGB1
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-173 10.03 SSB IL10
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-179 10.03 HMGB1 SSB IL10 APOH IL2RA
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-181 10.03 HMGB1 IL2RA
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-213 10.03 IL2RA
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-27 10.03 SSB
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-34 10.03 IL10 IL2RA
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-53 10.03 IL10
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-55 10.03 APOH
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-65 10.03 SSB IL10
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-68 10.03 IL10
16 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.77 IL2RA CD40LG SSB TNF IL10 IL1B
17 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.77 IL2RA CD40LG SSB TNF IL10 IL1B

MGI Mouse Phenotypes related to Rheumatic Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.07 VCAM1 CENPA CRP PTGS2 IFNG IL10
2 hematopoietic system MP:0005397 10.06 TRIM21 VCAM1 IL2RA PTGS2 IFNG SSB
3 homeostasis/metabolism MP:0005376 10.03 TRIM21 VCAM1 IL2RA CRP PTGS2 IFNG
4 immune system MP:0005387 9.93 TRIM21 VCAM1 IL2RA CRP PTGS2 IFNG
5 integument MP:0010771 9.56 TNF TRIM21 IL1R1 PTGS2 IFNG IL10
6 mortality/aging MP:0010768 9.47 TRIM21 VCAM1 IL2RA CENPB PTGS2 IFNG

Drugs & Therapeutics for Rheumatic Disease

Drugs for Rheumatic Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 934)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 1959-05-2, 59-05-2 126941
2
Hydroxychloroquine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 118-42-3 3652
3
Infliximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 170277-31-3
4
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 83-43-2 6741
5
Naltrexone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 16590-41-3 5360515
6
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-24-8 5755
7
Sulfasalazine Approved Phase 4,Phase 3,Phase 2,Not Applicable 599-79-1 5353980 5359476
8
Etanercept Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 185243-69-0
9
Menthol Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 2216-51-5 16666
10
Leflunomide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 75706-12-6 3899
11
Triamcinolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 124-94-7 31307
12
Acetylcholine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-84-3 187
13
Acetaminophen Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 103-90-2 1983
14
Hyaluronic acid Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 9004-61-9 53477741
15
Iron Approved Phase 4,Phase 3,Phase 1,Phase 2 7439-89-6 23925
16
Rivaroxaban Approved Phase 4,Phase 3,Not Applicable 366789-02-8
17
Tranexamic Acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1197-18-8 5526
18
Tranylcypromine Approved, Investigational Phase 4 155-09-9 441233
19
Celecoxib Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 169590-42-5 2662
20
Esomeprazole Approved, Investigational Phase 4,Phase 3,Phase 1,Not Applicable 161796-78-7, 119141-88-7 4594 9579578
21
Naproxen Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 22204-53-1 1302 156391
22
Bupivacaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 2180-92-9, 38396-39-3 2474
23
Spironolactone Approved Phase 4 1952-01-7, 52-01-7 5833
24
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 50-02-2 5743
25
Ropivacaine Approved Phase 4,Phase 3,Phase 2,Not Applicable 84057-95-4 71273 175805
26
Cimetidine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 51481-61-9 2756
27
Hyoscyamine Approved Phase 4 101-31-5 64692
28
Milnacipran Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 92623-85-3 65833
29
Norepinephrine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-41-2 439260
30
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1994-09-7, 94-09-7 2337
31
Etoricoxib Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 202409-33-4 123619
32
Adalimumab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 331731-18-1 16219006
33
Fluorouracil Approved Phase 4 51-21-8 3385
34
Tacrolimus Approved, Investigational Phase 4,Phase 3,Early Phase 1 104987-11-3 445643 439492
35
Diclofenac Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 15307-86-5 3033
36
Abatacept Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 332348-12-6 10237
37
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 174722-31-7 10201696
38
Amitriptyline Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 50-48-6 2160
39
Cyclobenzaprine Approved Phase 4,Phase 3,Phase 2,Not Applicable 303-53-7 2895
40
Certolizumab pegol Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 428863-50-7
41
Epinephrine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-43-4 5816
42
Ketorolac Approved Phase 4,Phase 3,Phase 2,Not Applicable 74103-06-3, 66635-83-4 3826
43
Morphine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 57-27-2 5288826
44
Racepinephrine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 329-65-7 838
45
Calcium Carbonate Approved, Investigational Phase 4,Phase 3,Phase 2 471-34-1
46
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-18-0, 6055-19-2 2907
47
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
48
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 53-03-2 5865
49
Betamethasone Approved, Vet_approved Phase 4,Phase 3,Not Applicable 378-44-9 9782
50
Aminocaproic Acid Approved, Investigational Phase 4,Phase 2,Not Applicable 60-32-2 564

Interventional clinical trials:

(show top 50) (show all 6273)
# Name Status NCT ID Phase Drugs
1 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
2 Uncontrolled Study to Evaluate Efficacy of Tocilizumab in Patients With Moderate or Severe Rheumatoid Arthritis Unknown status NCT02087696 Phase 4 Tocilizumab
3 Vaccination Against Pertussis, Tetanus and Diphtheria in Patients Suffering From Rheumatoid Arthritis Unknown status NCT01301703 Phase 4
4 TNF-blocking Therapy in Combination With Disease-modifying Antirheumatic Drugs in Early Rheumatoid Arthritis Unknown status NCT00908089 Phase 4 Trexan+Salazopyrin+Oxiklorin+prednisolone + infliximab;Trexan+Salazopyrin+Oxiklorin+prednisolone + placebo
5 Very Early Versus Delayed Etanercept in Patients With RA Unknown status NCT02433184 Phase 4 Etanercept;Methotrexate;Sulfasalazine;Hydroxychloroquine;Etanercept;Methotrexate
6 Remission Induction in Very Early Rheumatoid Arthritis Unknown status NCT00523692 Phase 4 Etanercept, methotrexate and depomedrone;depemedrone
7 Efficacy Study of Leflunomide to Treat Juvenile Idiopathic Arthritis Unknown status NCT02024334 Phase 4 Leflunomide
8 Targeting Synovitis in Early Rheumatoid Arthritis Unknown status NCT00920478 Phase 4
9 Obesity Cohort : Medical Follow-up of Severe or Morbid Obese Patients Undergoing Bariatric Surgery Unknown status NCT02310178 Phase 4
10 Influence of Perception of Patients Suffering of Knee Osteoarthritis Regarding Effectiveness of Intra-articular Injection Unknown status NCT02835521 Phase 4 Joint injection with triamcinolone hexacetonide
11 Safety and Efficacy of Intra-articular Ozone Injections for Knee Osteoarthritis Unknown status NCT02833545 Phase 4
12 Intra-articular Botox Type A Versus Corticosteroids in Knee Osteoarthritis Unknown status NCT02829281 Phase 4 Botulinum Toxin Type A;Triamcinolone hexacetonide;Saline
13 Evaluation of the Evolution of Imaging Markers of Cartilage Degradation in Patients With Knee Osteoarthritis Receiving DROGLICAN Unknown status NCT02821468 Phase 4 Droglican;Paracetamol or oral NSAIDs excluding COX2 inhibitors
14 Assessment of a Knee Brace in Patients With Osteoarthritis Unknown status NCT02706106 Phase 4
15 Effectiveness of Trapeziometacarpal Splint Unknown status NCT02635932 Phase 4
16 Effects of Hyaluronic Acid vs. Hyaluronic Acid on Knee Osteoarthritis Unknown status NCT02625727 Phase 4
17 Intravenous Iron Sucrose in Arthroplasty Unknown status NCT02544828 Phase 4 Iron Sucrose 200mg;placebo
18 Does Intraoperative Intravenous Iron Enhance Postoperative Oxygenation Profile in Total Knee Arthroplasty Surgery? Unknown status NCT02544464 Phase 4 ferric carboxymaltose 1000 mg;placebo
19 The Post-marketing Surveillance to Evaluate the Efficacy of CHONDRON (Autologous Cultured Chondrocyte) by Arthroscopy Unknown status NCT02539069 Phase 4
20 The Post-marketing Surveillance to Evaluate the Efficacy and Safety of a CHONDRON (Autologous Cultured Chondrocyte) Unknown status NCT02539056 Phase 4
21 Multi-center Clinical Study of Guli Capsules in the Treatment of Knee Osteoarthritis Unknown status NCT02484508 Phase 4 Guli capsule;Kangguzengsheng capsule
22 Comparison of Topical and Infusion Tranexamic Acid After Total Knee Arthroplasty Unknown status NCT02453802 Phase 4 Tranexamic Acid 5%,5ml/amp;Tranexamic Acid 5%,5ml/amp;rivaroxaban (10mg);0.9% Normal Saline;0.9% Normal Saline
23 Validation of a Stress Device for the Knee Unknown status NCT02444663 Phase 4
24 Gastro-protective Effect and Pain Relief Effect of Naxozol Compared to Celecoxib in Patients With Osteoarthritis Unknown status NCT02355236 Phase 4 Naproxen/Esomeprazol 500/20mg;Celecoxib 200mg;Naxozol-Placebo;Comparator-Placebo
25 Medical Chitosan or Sodium Hyaluronate for Knee Osteoarthritis (CHOOSE) Unknown status NCT02323451 Phase 4 Sodium Hyaluronate Injection
26 Tranexamic Acid in Knee Joint Surgery Unknown status NCT02278263 Phase 4 Tranexamic Acid;Normal saline (0.9% NaCl)
27 Comparison of Floseal® and Tranexamic Acid on Bleeding Control After Total Knee Arthroplasty Unknown status NCT02152917 Phase 4 Tranexamic acid;Floseal®
28 Intraarticular Xylitol Injections for Knee Osteoarthritis Unknown status NCT02104596 Phase 4
29 Daily Activity and Gait Analysis After Viscosupplement Injection Among Hip Osteoarthritis Patients Unknown status NCT02086474 Phase 4 Hyaluronan;Bupivacaine
30 The Effect of Spironolactone on Pain in Older People With Osteoarthritis Unknown status NCT02046668 Phase 4 spironolactone
31 Outcome Comparison of Allograft and Synthetic Bone Substitute in High Tibial Osteotomy Unknown status NCT02000297 Phase 4
32 A Phase 4 Study of Imrecoxib in Treatment of Knee Osteoarthritis Unknown status NCT01985165 Phase 4 Imrecoxib
33 Comparison of Femoral Nerve Catheter and Adductor Canal Block With Steroid Adjuvant in Total Knee Replacement (TKR) Unknown status NCT01973530 Phase 4
34 Reinflation After Early Tourniquet Release in Total Knee Arthroplasty Unknown status NCT01832272 Phase 4
35 Hip Viscosupplementation: What is the Best Dosage? Unknown status NCT01810809 Phase 4 1 ampoule of Hylan GF-20;2 ampoules of Hylan GF-20;3 ampoules of Hylan GF-20
36 Bone Forming at Prosthetic Surfaces. Fingerprint2 Unknown status NCT01623687 Phase 4
37 RSA Study Using Two Types of Uncemented Acetabular Components and the Uncemented HA Coated Symax Stem Unknown status NCT01618084 Phase 4
38 Study to Evaluate the Efficacy of Milnacipran in the Treatment of Pain Due to Osteoarthritis Unknown status NCT01329406 Phase 4 Milnacipran;Placebo
39 Chondroitin Sulphate Treatment Efficacy in Rhizarthrosis. Unknown status NCT01233739 Phase 4 Chondroitin sulfate;Placebo
40 Assessment of the Effects of Chondroitin Sulphate in Patients With Knee Osteoarthritis With Functional Magnetic Resonance Imaging (fMRI) Unknown status NCT01226615 Phase 4 Chondroitin sulphate (Condrosan®);Placebo
41 Prophecy Guide Outcomes in Total Knee Replacement Surgery Unknown status NCT01163708 Phase 4
42 Comparison of Outcomes in Mobile and Fixed-bearing Total Knee Arthroplasty Unknown status NCT01027819 Phase 4
43 The Impact of Hyaluronic Acid Injections on Osteoarthritic Knee Mechanics Unknown status NCT00778076 Phase 4
44 Use of Cold and Compression Therapy With Total Knee Replacement Patients Unknown status NCT00712816 Phase 4
45 Trial Comparing Navigated and Conventional Implantation Techniques in Knee Replacement Surgery Unknown status NCT00431509 Phase 4
46 The Effect of Intraaricular Knee Injections of Hyaluronic Acid (HA) on Bone and Cartilaginous Debris, as a Therapeutic Indicator Unknown status NCT00422643 Phase 4 Sodium hyaluronate (hyaluronic acid)
47 Effectiveness Study of Hylan G-F 20 to Preserve Cartilage in Osteoarthritis of the Knee Unknown status NCT00393393 Phase 4 intra-articular injection of Hylan G-F 20
48 Effect of Flex-a-New on Osteoarthritis of the Knee Unknown status NCT00294801 Phase 4 flex-a-new (food supplement)
49 Comparing Clinical Outcome of 2 Different Total Knee Prostheses: Nexgen LPS-Flex Versus AGC Unknown status NCT00294528 Phase 4
50 Efficacy of Celecoxib Vs Placebo to Prevent Pain in a Paced Walk Unknown status NCT00194090 Phase 4 celecoxib

Search NIH Clinical Center for Rheumatic Disease

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Genetic Tests for Rheumatic Disease

Anatomical Context for Rheumatic Disease

MalaCards organs/tissues related to Rheumatic Disease:

41
Bone, Testes, Heart, Eye, Bone Marrow, Brain, Skin

Publications for Rheumatic Disease

Articles related to Rheumatic Disease:

(show top 50) (show all 950)
# Title Authors Year
1
Approach to Patients with Suspected Rheumatic Disease. ( 29759118 )
2018
2
Development of neoplasms in pediatric patients with rheumatic disease exposed to anti-tumor necrosis factor therapies: a single Centre retrospective study. ( 29540190 )
2018
3
Confidence amongst Multidisciplinary Professionals in Managing Paediatric Rheumatic Disease in Australia. ( 29593902 )
2018
4
Retinal Vessel Diameters and Physical Activity in Patients With Mild to Moderate Rheumatic Disease Without Cardiovascular Comorbidities. ( 29593551 )
2018
5
Prescribing for Children with Rheumatic Disease: Perceived Treatment Approaches between Pediatric and Adult Rheumatologists. ( 29481725 )
2018
6
Can we prescribe TMP/SMX prophylaxis without any concerns equally for all patients with rheumatic disease? ( 29437584 )
2018
7
Cancer Immunotherapy in Patients With Preexisting Rheumatic Disease: The Mayo Clinic Experience. ( 29363290 )
2018
8
Patient satisfaction and efficacy of switching from weekly bisphosphonates to monthly minodronate for treatment and prevention of glucocorticoid-induced osteoporosis in Japanese patients with systemic rheumatic diseases: a randomized, clinical trial. ( 29904824 )
2018
9
Prevalence of anti-DFS70 antibodies in patients with and without systemic autoimmune rheumatic diseases. ( 28770702 )
2018
10
Rapid glucocorticoid tapering therapy to reduce mortality from pneumocystis pneumonia in patients with rheumatic disease. ( 29972334 )
2018
11
Correction to: Progressive multifocal leukoencephalopathy in rituximab-treated rheumatic diseases: a rare event. ( 29637430 )
2018
12
The Brave New World of Rheumatic Disease Research Today. ( 29622303 )
2018
13
Biosimilars: An opportunity. Position statement of the French Rheumatology Society (SFR) and Inflammatory Rheumatic Disease Club (CRI). ( 29574143 )
2018
14
Effectiveness and Drug Survival of Anti-Tumor Necrosis Factor I+ Therapies in Patients With Spondyloarthritis: Analysis From the Thai Rheumatic Disease Prior Authorization Registry. ( 29517554 )
2018
15
Asymptomatic Rhabdomyolysis and Digital Necrosis-Clues for a Rheumatic Disease. ( 29742540 )
2018
16
Response to: 'Can we prescribe TMP/SMX prophylaxis without any concerns equally for all patients with rheumatic disease?' by Suyama and Okada. ( 29437583 )
2018
17
Rheumatic Disease: Protease-Activated Receptor-2 in Synovial Joint Pathobiology. ( 29875735 )
2018
18
Endothelial progenitor cells and rheumatic disease modifying therapy. ( 29842927 )
2018
19
Rheumatic Disease Autoantibodies in Patients with Autoimmune Thyroid Diseases. ( 29864750 )
2018
20
The Impact of Biologics and Tofacitinib on Cardiovascular Risk Factors and Outcomes in Patients with Rheumatic Disease: A Systematic Literature Review. ( 29318514 )
2018
21
Identification of new biomarkers to promote personalised treatment of patients with inflammatory rheumatic disease: protocol for an open cohort study. ( 29391382 )
2018
22
Predictors for influenza vaccine acceptance among patients with inflammatory rheumatic diseases. ( 29980390 )
2018
23
Treatment patterns among patients with rheumatic disease (rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA) and undifferentiated arthritis (UnA)) treated with subcutaneous TNF inhibitors. ( 29667098 )
2018
24
Rice-body formation without rheumatic disease or tuberculosis in a &amp;quot;sausage&amp;quot; ring finger. ( 29786532 )
2018
25
Translating GWAS in rheumatic disease: approaches to establishing mechanism and function for genetic associations with ankylosing spondylitis. ( 29741584 )
2018
26
Determination of Specificity and Pattern of Antinuclear Antibodies (ANA) in Systemic Rheumatic Disease Patients Positive for ANA Testing. ( 29290190 )
2018
27
The rheumatic disease-associated FAM167A-BLK locus encodes DIORA-1, a novel disordered protein expressed highly in bronchial epithelium and alveolar macrophages. ( 29663334 )
2018
28
Sexual and reproductive health in rheumatic disease. ( 28680137 )
2017
29
Filling the gaps in SARDs research: collection and linkage of administrative health data and self-reported survey data for a general population-based cohort of individuals with and without diagnoses of systemic autoimmune rheumatic disease (SARDs) from British Columbia, Canada. ( 28637725 )
2017
30
Systematic review and meta-analysis of the epidemiology of polyautoimmunity in SjAPgren's syndrome (secondary SjAPgren's syndrome) focusing on autoimmune rheumatic diseases. ( 28927315 )
2017
31
Clinical characteristics of autoimmune rheumatic disease-related organizing pneumonia. ( 28748510 )
2017
32
Re: Did King Herod suffer from a rheumatic disease? doi: 10.1007/s10067-017-3583-z. ( 28733792 )
2017
33
Ehlers-Danlos syndrome hypermobility type is associated with rheumatic diseases. ( 28051109 )
2017
34
Macrophage Activation Syndrome in Paediatric Rheumatic Diseases. ( 28588173 )
2017
35
Paediatric rheumatic disease: Systemic JIA genetically distinct. ( 28077866 )
2017
36
Simple screening tools predict death and cardiovascular events in patients with rheumatic disease. ( 28812405 )
2017
37
Adaptation to inflammatory rheumatic disease: Do illness representations predict patients' physical functioning over time? A complex relationship. ( 28936564 )
2017
38
The endocannabinoid system in pain and inflammation: Its relevance to rheumatic disease. ( 29164003 )
2017
39
Mortality causes and outcomes in Indigenous populations of Canada, the United States, and Australia with rheumatic disease: A systematic review. ( 28823732 )
2017
40
Biologic Agents in the Treatment of Childhood-Onset Rheumatic Disease. ( 28711176 )
2017
41
Post-Chikungunya Rheumatic Disease in a 13-Year-Old Boy. ( 28884916 )
2017
42
Clinical and ultrasonographic enthesopathy in inflammatory rheumatic diseases : Is MASEI or only calcaneal enthesitis sufficient? ( 29116386 )
2017
43
Paediatric rheumatic disease: What is the best definition of clinical remission in JIA? ( 28725036 )
2017
44
Development, Sensibility, and Validity of a Systemic Autoimmune Rheumatic Disease Case Ascertainment Tool. ( 27803141 )
2017
45
The complement system as a potential therapeutic target in rheumatic disease. ( 28794515 )
2017
46
Paediatric rheumatic disease: Multi-pronged approach uncovers sJIA mechanisms. ( 29021570 )
2017
47
Robot-Assisted Mitral Valve Repair With Posterior Leaflet Extension for Rheumatic Disease. ( 28085691 )
2017
48
What do young people with rheumatic disease believe to be important to research about their condition? A UK-wide study. ( 28673355 )
2017
49
The Role of Monocyte Percentage in Osteoporosis in Male Rheumatic Diseases. ( 28901203 )
2017
50
Neutrophilic urticarial dermatosis: a novel association with poststreptococcal rheumatic disease. ( 29271002 )
2017